Your browser doesn't support javascript.
loading
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer.
Prasad, Manu; Zorea, Jonathan; Jagadeeshan, Sankar; Shnerb, Avital B; Mathukkada, Sooraj; Bouaoud, Jebrane; Michon, Lucas; Novoplansky, Ofra; Badarni, Mai; Cohen, Limor; Yegodayev, Ksenia M; Tzadok, Sapir; Rotblat, Barak; Brezina, Libor; Mock, Andreas; Karabajakian, Andy; Fayette, Jérôme; Cohen, Idan; Cooks, Tomer; Allon, Irit; Dimitstein, Orr; Joshua, Benzion; Kong, Dexin; Voronov, Elena; Scaltriti, Maurizio; Carmi, Yaron; Conde-Lopez, Cristina; Hess, Jochen; Kurth, Ina; Morris, Luc G T; Saintigny, Pierre; Elkabets, Moshe.
Affiliation
  • Prasad M; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Zorea J; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Jagadeeshan S; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Shnerb AB; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Mathukkada S; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Bouaoud J; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Michon L; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Novoplansky O; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Badarni M; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Cohen L; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Yegodayev KM; Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, France.
  • Tzadok S; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.
  • Rotblat B; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.
  • Brezina L; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Mock A; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Karabajakian A; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Fayette J; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Cohen I; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Cooks T; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Allon I; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Dimitstein O; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Joshua B; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Kong D; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Voronov E; Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Scaltriti M; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Carmi Y; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Conde-Lopez C; Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Hess J; Division of Translational Medical Oncology, NCT Heidelberg, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
  • Kurth I; Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, France.
  • Morris LGT; Univ Lyon, Université Claude Bernard Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69373, France.
  • Saintigny P; Department of Medical Oncology, Centre Léon Bérard, Lyon 69373, France.
  • Elkabets M; Department of Translational Medicine Oncology, Centre Léon Bérard, Lyon 69373, France.
J Immunother Cancer ; 10(3)2022 03.
Article in En | MEDLINE | ID: mdl-35292516
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Immunother Cancer Year: 2022 Type: Article Affiliation country: Israel
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Microenvironment / Head and Neck Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: J Immunother Cancer Year: 2022 Type: Article Affiliation country: Israel